Press Releases April 29, 2026 04:20 PM

Toll Brothers Announces New Phase of Home Sites Now Open at Oakbridge Crossing in Flower Mound, Texas

Toll Brothers launches new luxury home phase in Flower Mound, Texas, expanding premium single-family offerings.

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
TOL

Toll Brothers, the leading luxury home builder, announced the release of a new phase of home sites at Oakbridge Crossing in Flower Mound, Texas. The community offers high-end single-family homes priced from $1.49 million, with spacious designs and proximity to highly rated schools and amenities. Quick move-in homes are available with expected delivery by September 2026.

Toll Brothers Announces New Phase of Home Sites Now Open at Oakbridge Crossing in Flower Mound, Texas
TOL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Launch of new home phase at Oakbridge Crossing with prices starting at $1.49 million.
  • Offers luxurious single-family homes with 4-6 bedrooms and multiple garage options designed for various lifestyles.
  • Prime location near top-rated schools, major highways, and upscale shopping and entertainment in the Dallas-Fort Worth area.

FLOWER MOUND, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, announced the release of a new phase of home sites at Oakbridge Crossing, a luxury single-family home community in the prominent Dallas-Fort Worth town of Flower Mound, Texas. With pricing starting from $1.49 million, this new phase offers spacious home sites and elegant home designs in a highly desirable location.

“This community offers the perfect combination of luxurious home designs, excellent schools, and a prime location near shopping, dining, and entertainment,…”
“We are thrilled to introduce this new phase of home sites at Oakbridge Crossing,”
“This community offers the perfect combination of luxurious home designs, excellent schools, and a prime location near shopping, dining, and entertainment,…”
“We are thrilled to introduce this new phase of home sites at Oakbridge Crossing,”
“This community offers the perfect combination of luxurious home designs, excellent schools, and a prime location near shopping, dining, and entertainment,…”

Oakbridge Crossing features a collection of stunning one- and two-story single-family homes, with options ranging from 4 to 6 bedrooms and 4.5 to 6 bathrooms. Each home offers 3- or 4-car garages and luxurious living spaces designed to suit a variety of lifestyles. Home shoppers will also appreciate the community’s proximity to Flower Mound’s highly rated schools, including Bluebonnet Elementary and Shadow Ridge Middle Schools, both located less than a mile away.


Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The Design Studio allows home shoppers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants. Quick move-in homes with Designer Appointed Features are also available in the community with delivery dates as early as September 2026.

“We are thrilled to introduce this new phase of home sites at Oakbridge Crossing,” said Jay Saunders, Division President of Toll Brothers in Dallas-Fort Worth. “This community offers the perfect combination of luxurious home designs, excellent schools, and a prime location near shopping, dining, and entertainment, making it a wonderful place to call home.”


Oakbridge Crossing is conveniently located near major thoroughfares, including Highways 121, 114, and 635, as well as Interstate 35E, offering easy access to the Dallas-Fort Worth metroplex. Residents will also enjoy proximity to The Shops at Lakeside, which features boutique shopping, upscale dining, and entertainment options.

The Toll Brothers Sales Center is located at 1209 Valkyrie Sky Road in Flower Mound. For more information on Oakbridge Crossing, call  855-289-8656 or visit  TollBrothers.com/Dallas.

About Toll Brothers

Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses.

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | ameck@tollbrothers.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/01a57d83-296b-4298-8f17-2905ad78daf3

https://www.globenewswire.com/NewsRoom/AttachmentNg/cbcd6ed6-e7bb-4ec1-a084-2d92d54356f3 

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)


Risks

  • Customer demand may fluctuate affecting sales velocity in the luxury housing market.
  • Potential economic downturn or rising interest rates could impact buyer affordability and financing.
  • Construction or supply chain delays could postpone quick move-in home deliveries and overall community completion.

More from Press Releases

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026